Lista de obras -

Adaptive mutability of colorectal cancers in response to targeted therapies

scientific article published on 07 November 2019

BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS Mutant Colorectal Cancer

artículo científico publicado en 2016

Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.

artículo científico publicado en 2014

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

artículo científico publicado en 2015

Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer

artículo científico publicado en 2017

Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

scientific article published on 01 July 2015

Heat-shock protein 27 (HSP27, HSPB1) is synthetic lethal to cells with oncogenic activation of MET, EGFR and BRAF.

artículo científico publicado en 2017

High-dose vitamin C enhances cancer immunotherapy

artículo científico publicado en 2020

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.

artículo científico publicado en 2017

Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.

artículo científico publicado en 2010

Mixed lineage kinase MLK4 is activated in colorectal cancers where it synergistically cooperates with activated RAS signaling in driving tumorigenesis.

artículo científico publicado en 2013

Mutational profile of GNAQQ209 in human tumors.

artículo científico publicado en 2009

Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature

artículo científico publicado en 2016

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells

artículo científico publicado en 2014

Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies.

artículo científico publicado en 2018

Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels

artículo científico publicado en 2013

The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type.

artículo científico publicado en 2010

The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.

artículo científico publicado en 2014

Lista de obras de

Adaptive mutability of colorectal cancers in response to targeted therapies

BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS Mutant Colorectal Cancer

Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer

Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

Heat-shock protein 27 (HSP27, HSPB1) is synthetic lethal to cells with oncogenic activation of MET, EGFR and BRAF.

High-dose vitamin C enhances cancer immunotherapy

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.

Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.

Mixed lineage kinase MLK4 is activated in colorectal cancers where it synergistically cooperates with activated RAS signaling in driving tumorigenesis.

Mutational profile of GNAQQ209 in human tumors.

Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells

Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies.

Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels

The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type.

The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.